BYM338
Bimagrumab (BYM338)
N/A Amino Acids · MW: ~148 kDa
Amino Acids
N/A
Molecular Weight
~148 kDa
Half-life
~2-3 weeks
Research Score
4.7
Studies
140
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is BYM338?
A human monoclonal antibody against activin type II receptors that blocks myostatin/activin signaling at the receptor level. It has been studied for sarcopenia, obesity with muscle preservation, and several wasting conditions.
Key Benefits & Mechanisms
increased lean mass
functional strength support
reduced muscle wasting
metabolic body-composition shift
Research Summary
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Related Peptides
FS315
Follistatin-315 (FS315)
The circulating major isoform of follistatin that binds activins and can modulate myostatin signaling. It is widely used in research because it is the more common endogenous secreted form in human plasma.
Muscle & PerformanceACE-031
ACE-031 (soluble activin receptor type IIB-Fc)
A recombinant decoy receptor fusion protein that traps myostatin and related ligands such as activins. It was developed to promote skeletal muscle growth and counteract wasting.
Muscle & PerformanceREGN1033
Trevogrumab (REGN1033)
A human monoclonal antibody that neutralizes myostatin, the key negative regulator of skeletal muscle growth. It has been evaluated for muscle loss states and as a body-composition modulator in combination regimens.
Muscle & PerformanceEpoetin Alfa
Recombinant human erythropoietin alfa
Recombinant human erythropoietin alfa is a glycoprotein hormone that stimulates red blood cell production. In endurance contexts, its main effect is improving oxygen delivery and potentially raising VO2 max, but the safety margin is narrow.
Muscle & Performance